The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise

Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise

March 2, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Tofacitinib No Longer Requires REMS
The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for tofacitinib (Xeljanz 5 mg), eliminating the Risk Evaluation and Mitigation Strategy (REMS) requirement that was initially approved on Nov. 6, 2012, and modified on June 19, 2015.1 The REMS consisted of a communication plan and a timetable for submission of REMS assessments.

You Might Also Like
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
  • Etanercept Biosimilars Promising in Clinical Studies
  • Rheumatology Drug Updates: Biosimilars Receive Positive News & More
Also By This Author
  • Brentuximab Vedotin Enters Phase 2 Trials & More

CHS-0214 Shows Biosimilarity to Etanercept
CHS-0214, a proposed etanercept (Enbrel) biosimilar, met its primary endpoint of ACR20 at Week 24 in a Phase 3 clinical trial.2 In this study, CHS-0214 was compared with the safety and efficacy of etanercept in patients with moderate to severe rheumatoid arthritis (RA) that was inadequately controlled with methotrexate (MTX) monotherapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Compared with etanercept, CHS-0214 had no clinically meaningful differences in safety and immunogenicity. This current study will continue for 52 weeks. It’s the second Phase 3 trial of CHS-0214, which is manufactured by Baxalta.

In November 2015, CHS-0214 met its primary endpoints for the treatment of patients with chronic plaque psoriasis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Adalimumab Biosimilar Accepted for FDA Review
The FDA has assigned a decision due date of Sept. 25, 2016, for evaluating the biologics license application (BLA) for ABP-501, Amgen’s adalimumab (Humira) biosimilar.3 Submitted in 2015, patients with moderate to severe RA and moderate to severe plaque psoriasis met primary safety and clinical efficacy endpoints. ABP-501 showed no clinically meaningful differences to adalimumab in Phase 3 clinical trials.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Han DH. Xeljanz released from REMS requirement. MPR. 2016 Feb 10.
  2. Anekwe L. Baxalta’s Enbrel biosimilar measures up in late-stage study. Pharmafile.com. 2016 Jan 13.
  3. Levy J. FDA to review Amgen’s Humira biosimilar. Pharmafile.com. 2016 Jan 16.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, etanercept, FDA, Food and Drug Administration, Tofacitinib

You Might Also Like:
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
  • Etanercept Biosimilars Promising in Clinical Studies
  • Rheumatology Drug Updates: Biosimilars Receive Positive News & More
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.